ImmunityBio
IBRX
62 hedge funds and large institutions have $174M invested in ImmunityBio in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 10 closing their positions.
473% more call options, than puts
Call options by funds: $1.43M | Put options by funds: $249K
100% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 13
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
2% more funds holding
Funds holding: 61 → 62 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
52% less capital invested
Capital invested by funds: $363M → $174M (-$190M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.17M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.09M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
+$764K |
| 4 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$398K |
| 5 |
CC
Callan Capital
La Jolla,
California
|
+$364K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$3.81M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.54M |
| 3 |
Goldman Sachs
New York
|
-$1.29M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$841K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$803K |
IBRX Hedge Fund Activity: Q1 2016 in Review
62 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2016, worth a combined $174M — down 52% from $363M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new IBRX positions and 10 closed out — a net gain of 1 holder — while 26 added to existing stakes and 13 trimmed.
The largest buyer was Vanguard Group, adding an estimated $6.17M. The largest seller was Avoro Capital Advisors, cutting an estimated $3.81M.
- 62 institutional investors held ImmunityBio (IBRX) as of Q1 2016, up from 61 in Q4 2015.
- Funds reported $174M of ImmunityBio stock for Q1 2016, down 52% quarter-over-quarter.
- 11 funds opened new ImmunityBio positions in Q1 2016 and 10 closed out, a net change of +1 holder.
- The largest ImmunityBio buyer in Q1 2016 was Vanguard Group, an estimated $6.17M added.
- The largest ImmunityBio seller in Q1 2016 was Avoro Capital Advisors, an estimated $3.81M sold.
Based on aggregated 13F filings for Q1 2016.